Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.03
NYSE:TEVA's Cash-to-Debt is ranked lower than
98% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. NYSE:TEVA: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:TEVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.3 Max: 1.03
Current: 0.03
0.03
1.03
Equity-to-Asset 0.36
NYSE:TEVA's Equity-to-Asset is ranked lower than
82% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. NYSE:TEVA: 0.36 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:TEVA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.5 Max: 0.59
Current: 0.36
0.36
0.59
Interest Coverage 3.90
NYSE:TEVA's Interest Coverage is ranked lower than
84% of the 646 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. NYSE:TEVA: 3.90 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:TEVA' s Interest Coverage Range Over the Past 10 Years
Min: 3.6  Med: 11.95 Max: 19.16
Current: 3.9
3.6
19.16
Piotroski F-Score: 3
Altman Z-Score: 0.83
Beneish M-Score: -2.28
WACC vs ROIC
4.43%
3.13%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 9.83
NYSE:TEVA's Operating Margin % is ranked higher than
54% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.38 vs. NYSE:TEVA: 9.83 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:TEVA' s Operating Margin % Range Over the Past 10 Years
Min: 8.12  Med: 17.02 Max: 25.46
Current: 9.83
8.12
25.46
Net Margin % 1.50
NYSE:TEVA's Net Margin % is ranked lower than
68% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. NYSE:TEVA: 1.50 )
Ranked among companies with meaningful Net Margin % only.
NYSE:TEVA' s Net Margin % Range Over the Past 10 Years
Min: 1.5  Med: 12.03 Max: 20.75
Current: 1.5
1.5
20.75
ROE % 0.21
NYSE:TEVA's ROE % is ranked lower than
72% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.12 vs. NYSE:TEVA: 0.21 )
Ranked among companies with meaningful ROE % only.
NYSE:TEVA' s ROE % Range Over the Past 10 Years
Min: 0.21  Med: 10 Max: 16.18
Current: 0.21
0.21
16.18
ROA % 0.46
NYSE:TEVA's ROA % is ranked lower than
69% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. NYSE:TEVA: 0.46 )
Ranked among companies with meaningful ROA % only.
NYSE:TEVA' s ROA % Range Over the Past 10 Years
Min: 0.45  Med: 4.98 Max: 9.34
Current: 0.46
0.45
9.34
ROC (Joel Greenblatt) % 18.36
NYSE:TEVA's ROC (Joel Greenblatt) % is ranked higher than
56% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.08 vs. NYSE:TEVA: 18.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:TEVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 16.82  Med: 33.66 Max: 49.49
Current: 18.36
16.82
49.49
3-Year Revenue Growth Rate -1.60
NYSE:TEVA's 3-Year Revenue Growth Rate is ranked lower than
71% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. NYSE:TEVA: -1.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:TEVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.6  Med: 15.6 Max: 23.4
Current: -1.6
-1.6
23.4
3-Year EBITDA Growth Rate -8.00
NYSE:TEVA's 3-Year EBITDA Growth Rate is ranked lower than
79% of the 536 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. NYSE:TEVA: -8.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:TEVA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -9.6  Med: 12.3 Max: 47.4
Current: -8
-9.6
47.4
3-Year EPS without NRI Growth Rate -63.90
NYSE:TEVA's 3-Year EPS without NRI Growth Rate is ranked lower than
98% of the 506 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. NYSE:TEVA: -63.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:TEVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -63.9  Med: 11.1 Max: 68.2
Current: -63.9
-63.9
68.2
GuruFocus has detected 6 Warning Signs with Teva Pharmaceutical Industries Ltd $NYSE:TEVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:TEVA's 10-Y Financials

Financials (Next Earnings Date: 2017-05-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

TEVA Guru Trades in Q1 2016

David Dreman 33,983 sh (New)
Signature Select Canadian Fund 97,300 sh (New)
Jim Simons 1,191,263 sh (+123.71%)
NWQ Managers 1,961,208 sh (+42.10%)
Andreas Halvorsen 32,971,622 sh (+31.66%)
Keeley Asset Management Corp 43,784 sh (+20.34%)
Vanguard Health Care Fund 6,356,700 sh (+9.60%)
Ray Dalio 24,700 sh (+2.49%)
John Paulson 20,602,200 sh (+0.95%)
Ronald Muhlenkamp 177,160 sh (+0.12%)
NWQ Managers 41,600 sh (unchged)
Michael Price 440,300 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 399,000 sh (unchged)
Pioneer Investments Sold Out
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
John Griffin 3,988,300 sh (-0.29%)
Manning & Napier Advisors, Inc 111,192 sh (-1.79%)
Barrow, Hanley, Mewhinney & Strauss 9,315,460 sh (-2.99%)
Larry Robbins 5,579,312 sh (-6.32%)
Richard Snow 1,142,923 sh (-9.46%)
Julian Robertson 356,200 sh (-40.16%)
First Eagle Investment 1,915,660 sh (-56.18%)
Paul Tudor Jones 10,782 sh (-97.30%)
» More
Q2 2016

TEVA Guru Trades in Q2 2016

Jeremy Grantham 287,300 sh (New)
Barrow, Hanley, Mewhinney & Strauss 22,700,812 sh (+143.69%)
Keeley Asset Management Corp 58,169 sh (+32.85%)
Jim Simons 1,387,763 sh (+16.50%)
Manning & Napier Advisors, Inc 116,302 sh (+4.60%)
Eaton Vance Worldwide Health Sciences Fund 542,000 sh (+35.84%)
Vanguard Health Care Fund 6,356,700 sh (unchged)
Ray Dalio 24,700 sh (unchged)
Michael Price 440,300 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Julian Robertson Sold Out
Paul Tudor Jones Sold Out
Ronald Muhlenkamp 176,655 sh (-0.29%)
David Dreman 33,274 sh (-2.09%)
Richard Snow 1,076,039 sh (-5.85%)
NWQ Managers 1,677,841 sh (-14.45%)
Andreas Halvorsen 27,736,655 sh (-15.88%)
John Paulson 16,773,800 sh (-18.58%)
Larry Robbins 3,082,847 sh (-44.75%)
John Griffin 1,415,000 sh (-64.52%)
First Eagle Investment 200 sh (-99.99%)
» More
Q3 2016

TEVA Guru Trades in Q3 2016

Paul Tudor Jones 5,930 sh (New)
NWQ Managers 2,663,631 sh (+58.75%)
Jim Simons 1,947,963 sh (+40.37%)
Jeremy Grantham 336,700 sh (+17.19%)
Barrow, Hanley, Mewhinney & Strauss 26,570,988 sh (+17.05%)
Michael Price 469,300 sh (+6.59%)
Vanguard Health Care Fund 6,746,400 sh (+6.13%)
First Eagle Investment 200 sh (unchged)
Ray Dalio 24,700 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 542,000 sh (unchged)
John Griffin Sold Out
Ronald Muhlenkamp 175,770 sh (-0.50%)
Keeley Asset Management Corp 56,869 sh (-2.23%)
Manning & Napier Advisors, Inc 113,436 sh (-2.46%)
David Dreman 31,969 sh (-3.92%)
John Paulson 16,076,900 sh (-4.15%)
Richard Snow 965,986 sh (-10.23%)
Andreas Halvorsen 19,684,219 sh (-29.03%)
Larry Robbins 2,176,144 sh (-29.41%)
Signature Select Canadian Fund 40,500 sh (-58.38%)
» More
Q4 2016

TEVA Guru Trades in Q4 2016

Julian Robertson 554,800 sh (New)
David Tepper 5,053,000 sh (New)
Michael Price 696,500 sh (+48.41%)
Ronald Muhlenkamp 239,889 sh (+36.48%)
Vanguard Health Care Fund 8,922,300 sh (+32.25%)
Barrow, Hanley, Mewhinney & Strauss 32,455,432 sh (+22.15%)
Jim Simons 2,165,863 sh (+11.19%)
First Eagle Investment 200 sh (unchged)
Ray Dalio 24,700 sh (unchged)
Paul Tudor Jones Sold Out
Andreas Halvorsen Sold Out
Larry Robbins Sold Out
John Paulson 15,925,800 sh (-0.94%)
Manning & Napier Advisors, Inc 84,033 sh (-25.92%)
David Dreman 16,751 sh (-47.60%)
NWQ Managers 858,877 sh (-67.76%)
Keeley Asset Management Corp 16,603 sh (-70.80%)
Richard Snow 191,703 sh (-80.15%)
Jeremy Grantham 14,950 sh (-95.56%)
Eaton Vance Worldwide Health Sciences Fund 416,622 sh (-23.13%)
» More
» Details

Insider Trades

Latest Guru Trades with TEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Teva Pharmaceutical Industries Ltd

SymbolPriceYieldDescription
TEVVF640.2511.187 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:OTCPK:TKPYY, NAS:MYL, OTCPK:SGIOY, OTCPK:ESALF, OTCPK:MKGAY, NYSE:PRGO, OTCPK:MTZPY, OTCPK:APNHF, OTCPK:HLUYY, OTCPK:IPSEY, NYSE:RDY, OTCPK:HKMPF, OTCPK:HYPMY, NYSE:VRX, NYSE:TARO, NYSE:PTHN, NAS:OPK, OTCPK:STDAF, NAS:NBIX, NAS:MDCO » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVJF.USA,
Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Some of its products are Copaxone, Azilect & Provigil.

Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments generic and specialty medicines. The generics segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients ("API"). The specialty segment engages in the development, manufacture, sale and distribution of branded specialty medicines such as those for central nervous system and respiratory indications, as well as those marketed in the women's health, oncology and other specialty businesses. Its other activities include the over-the-counter ("OTC") medicines business, distribution activity mainly in Israel and Hungary and medical devices. The OTC activity is mainly conducted through a joint venture with P&G, which combines Company's production capabilities and market reach with P&G's marketing expertise and expansive platform. It has market presence in the United States, Europe and other markets. The Generic medicines include chemical and therapeutic equivalents of originator medicines in dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty medicines include several franchises in the core therapeutic areas of CNS medicines such as Copaxone, Azilect, Nuvigil and Zecuity and of respiratory medicines such as ProAir HFA and QVAR. It also includes other therapeutic areas, such as oncology medicines, including Treanda, women's health and selected other areas. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").

Guru Investment Theses on Teva Pharmaceutical Industries Ltd

John Keeley Comments on Teva Pharmaceuticals - Apr 26, 2016

Teva Pharmaceuticals (NYSE:TEVA) also had a challenging quarter. Although earnings were in-line with expectations, the company announced that its acquisition of Allergan’s generic pharmaceutical business would be delayed. Subsequent to the failure of the Pfizer/Allergan merger due to the proposed tax inversion regulatory changes, Teva announced that its acquisition of Allergan’s generic business remains on track to close in the second quarter of 2016.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Bernard Horn Comments on Teva Pharmaceutical - Mar 21, 2016

Teva Pharmaceutical (NYSE:TEVA) achieved strong profits, noting better-than-expected Copaxone sales. The company’s strategic initiatives, including the takeover of Allergan’s Actavis generic drug business and the joint venture with Takeda in Japan, were well received. This will further cement Teva’s position as the global leader in generics and help the company negotiate with its customers.

From Bernard Horn (Trades, Portfolio)'s Global Value Fund annual letter 2015.



Check out Bernard Horn latest stock trades

Vanguard Health Care Fund Comments on Teva Pharmaceutical Industries Ltd - Mar 27, 2015

We trimmed into strength our position in Teva (TEVA), an Israel-based global biopharmaceutical company specializing in generic formulations. The stock rose substantially on a combination of speculation around M&A in the sector, enthusiasm for the new CEO, and the strong conversion of once-daily Copaxone to the three-times-a-week version.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

David Tepper Invests Heavily in Pharma in 4th Quarter Guru gains 4 drug manufacturers, adds to Allergan
David Tepper (Trades, Portfolio), founder and president of Appaloosa Management, gained new holdings in pharmaceutical companies in the final quarter of 2016. Read more...
Teva: Good Value, Questionable Management? Teva Pharmaceutical shares lost half their value in 2016
4 Stocks Reach Their 3-Year Low Prices Teva Pharmaceutical and VF Corp. are trading near their historical low prices
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Fomento Economico Mexicano SAB de CV (NYSE:FMX), VF Corp. (NYSE:VFC) and Cerner Corp. (NASDAQ:CERN) have reached their three-year lows. Read more...
John Paulson’s Health Care Stocks Drop Far Below Sector Return Losses and redemptions mount despite Paulson's strong record
After years of uneven returns following his multi-billion-dollar profits shorting the subprime mortgage market in 2007, Paulson’s pain intensified this year as his outsized bet on the wrong health care stocks scuttled returns and spooked investors. Read more...
Allergan: An Undervalued Powerhouse After selling its generic units to Teva, Allergan has room for growth
Allergan (NYSE:AGN) is one of the largest pharmaceutical powerhouses, operating in many areas including eye care, facial aesthetics, plastic surgery, skin care and neuroscience and urology. Allergan’s history is quite interesting as the company has grown via many big acquisitions. Read more...
Andreas Halvorsen Buys Facebook, Amazon, MasterCard Guru's largest 1st-quarter buys
Andreas Halvorsen (Trades, Portfolio) is a founding partner of Viking Global Investors LP and currently serves as its CIO. During the first quarter he bought shares in the following stocks: Read more...
John Keeley Comments on Teva Pharmaceuticals Guru stock highlight
Teva Pharmaceuticals (NYSE:TEVA) also had a challenging quarter. Although earnings were in-line with expectations, the company announced that its acquisition of Allergan’s generic pharmaceutical business would be delayed. Subsequent to the failure of the Pfizer/Allergan merger due to the proposed tax inversion regulatory changes, Teva announced that its acquisition of Allergan’s generic business remains on track to close in the second quarter of 2016. Read more...
Health Care Investor Larry Robbins Buys HCA Holdings, Cigna Top 4th quarter buys from Glenview Capital founder
Glenview Capital Management, founded in 2000 by Larry Robbins (Trades, Portfolio), is a privately held investment management firm. During the fourth quarter, he bought shares in many stocks, including the following.  Read more...
Bernard Horn Comments on Teva Pharmaceutical Guru stock highlight
Teva Pharmaceutical (NYSE:TEVA) achieved strong profits, noting better-than-expected Copaxone sales. The company’s strategic initiatives, including the takeover of Allergan’s Actavis generic drug business and the joint venture with Takeda in Japan, were well received. This will further cement Teva’s position as the global leader in generics and help the company negotiate with its customers. Read more...
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Event and distressed strategies investor ups Valeant stake by 50%
John Paulson (Trades, Portfolio) is the president and portfolio manager of Paulson & Co. Inc. Paulson was ranked by Absolute Return Magazine as the third-largest hedge fund in the world managing approximately $29 billion in merger, event and distressed strategies. During the fourth quarter, the guru bought the following stocks. Read more...

Ratios

vs
industry
vs
history
PE Ratio 589.67
TEVA's PE Ratio is ranked lower than
99% of the 453 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.06 vs. TEVA: 589.67 )
Ranked among companies with meaningful PE Ratio only.
TEVA' s PE Ratio Range Over the Past 10 Years
Min: 10.49  Med: 20.67 Max: 938.25
Current: 589.67
10.49
938.25
Forward PE Ratio 7.63
TEVA's Forward PE Ratio is ranked higher than
90% of the 88 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.82 vs. TEVA: 7.63 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 589.67
TEVA's PE Ratio without NRI is ranked lower than
99% of the 447 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.19 vs. TEVA: 589.67 )
Ranked among companies with meaningful PE Ratio without NRI only.
TEVA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.49  Med: 20.67 Max: 938.25
Current: 589.67
10.49
938.25
Price-to-Owner-Earnings 15.01
TEVA's Price-to-Owner-Earnings is ranked higher than
81% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.27 vs. TEVA: 15.01 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TEVA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.02  Med: 16.43 Max: 67.1
Current: 15.01
9.02
67.1
PB Ratio 1.21
TEVA's PB Ratio is ranked higher than
83% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. TEVA: 1.21 )
Ranked among companies with meaningful PB Ratio only.
TEVA' s PB Ratio Range Over the Past 10 Years
Min: 1.1  Med: 2.17 Max: 3.68
Current: 1.21
1.1
3.68
PS Ratio 1.53
TEVA's PS Ratio is ranked higher than
71% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. TEVA: 1.53 )
Ranked among companies with meaningful PS Ratio only.
TEVA' s PS Ratio Range Over the Past 10 Years
Min: 1.39  Med: 2.73 Max: 5.35
Current: 1.53
1.39
5.35
Price-to-Free-Cash-Flow 7.76
TEVA's Price-to-Free-Cash-Flow is ranked higher than
90% of the 185 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.92 vs. TEVA: 7.76 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TEVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.06  Med: 13.79 Max: 33.07
Current: 7.76
7.06
33.07
Price-to-Operating-Cash-Flow 6.42
TEVA's Price-to-Operating-Cash-Flow is ranked higher than
85% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.34 vs. TEVA: 6.42 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TEVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.84  Med: 11.25 Max: 23.43
Current: 6.42
5.84
23.43
EV-to-EBIT 54.11
TEVA's EV-to-EBIT is ranked lower than
87% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.61 vs. TEVA: 54.11 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.4  Med: 20.95 Max: 991
Current: 54.11
11.4
991
EV-to-EBITDA 25.61
TEVA's EV-to-EBITDA is ranked lower than
72% of the 478 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.32 vs. TEVA: 25.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.5  Med: 14.35 Max: 290.6
Current: 25.61
8.5
290.6
Shiller PE Ratio 15.48
TEVA's Shiller PE Ratio is ranked higher than
90% of the 157 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.81 vs. TEVA: 15.48 )
Ranked among companies with meaningful Shiller PE Ratio only.
TEVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.06  Med: 26.29 Max: 58.88
Current: 15.48
14.06
58.88
Current Ratio 0.92
TEVA's Current Ratio is ranked lower than
88% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.25 vs. TEVA: 0.92 )
Ranked among companies with meaningful Current Ratio only.
TEVA' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.59 Max: 2.95
Current: 0.92
0.92
2.95
Quick Ratio 0.65
TEVA's Quick Ratio is ranked lower than
87% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. TEVA: 0.65 )
Ranked among companies with meaningful Quick Ratio only.
TEVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.65  Med: 1.08 Max: 2.18
Current: 0.65
0.65
2.18
Days Inventory 161.01
TEVA's Days Inventory is ranked lower than
72% of the 567 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.74 vs. TEVA: 161.01 )
Ranked among companies with meaningful Days Inventory only.
TEVA' s Days Inventory Range Over the Past 10 Years
Min: 161.01  Med: 186.4 Max: 208.14
Current: 161.01
161.01
208.14
Days Sales Outstanding 125.37
TEVA's Days Sales Outstanding is ranked lower than
80% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. TEVA: 125.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 123.91 Max: 153.21
Current: 125.37
95.91
153.21
Days Payable 78.39
TEVA's Days Payable is ranked higher than
56% of the 471 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. TEVA: 78.39 )
Ranked among companies with meaningful Days Payable only.
TEVA' s Days Payable Range Over the Past 10 Years
Min: 78.39  Med: 84.39 Max: 111.41
Current: 78.39
78.39
111.41

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.84
TEVA's Dividend Yield % is ranked higher than
89% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.62 vs. TEVA: 3.84 )
Ranked among companies with meaningful Dividend Yield % only.
TEVA' s Dividend Yield % Range Over the Past 10 Years
Min: 0.51  Med: 1.96 Max: 4.22
Current: 3.84
0.51
4.22
Dividend Payout Ratio 19.43
TEVA's Dividend Payout Ratio is ranked lower than
100% of the 378 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.36 vs. TEVA: 19.43 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TEVA' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14  Med: 0.42 Max: 19.43
Current: 19.43
0.14
19.43
3-Year Dividend Growth Rate 2.00
TEVA's 3-Year Dividend Growth Rate is ranked lower than
66% of the 270 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.20 vs. TEVA: 2.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
TEVA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 2  Med: 27 Max: 80.9
Current: 2
2
80.9
Forward Dividend Yield % 3.84
TEVA's Forward Dividend Yield % is ranked higher than
87% of the 612 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. TEVA: 3.84 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 12.74
TEVA's 5-Year Yield-on-Cost % is ranked higher than
96% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. TEVA: 12.74 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TEVA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 6.14  Med: 7.53 Max: 12.9
Current: 12.74
6.14
12.9
3-Year Average Share Buyback Ratio -2.30
TEVA's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. TEVA: -2.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.6  Med: -2.3 Max: 1.2
Current: -2.3
-12.6
1.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.56
TEVA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
95% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.61 vs. TEVA: 0.56 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TEVA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.56  Med: 1.24 Max: 7.38
Current: 0.56
0.56
7.38
Price-to-Median-PS-Value 0.56
TEVA's Price-to-Median-PS-Value is ranked higher than
91% of the 538 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.22 vs. TEVA: 0.56 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TEVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.13 Max: 2.04
Current: 0.56
0.56
2.04
Earnings Yield (Greenblatt) % 1.80
TEVA's Earnings Yield (Greenblatt) % is ranked lower than
65% of the 611 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. TEVA: 1.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TEVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 4.8 Max: 8.8
Current: 1.8
0.1
8.8
Forward Rate of Return (Yacktman) % 7.57
TEVA's Forward Rate of Return (Yacktman) % is ranked lower than
54% of the 353 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.48 vs. TEVA: 7.57 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TEVA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -4  Med: 14.9 Max: 40.2
Current: 7.57
-4
40.2

More Statistics

Revenue (TTM) (Mil) $21,903
EPS (TTM) $ 0.06
Beta0.62
Short Percentage of Float2.07%
52-Week Range $31.90 - 59.35
Shares Outstanding (Mil)1,014.99

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 23,421 23,606 24,088
EPS ($) 4.79 4.75 5.09
EPS without NRI ($) 4.79 4.75 5.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-0.37%
Dividends per Share ($) 1.36 1.50 1.65
» More Articles for TEVA

Headlines

Articles On GuruFocus.com
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 
Beaten-Down Valuation and a 3% Dividend Yield Feb 07 2017 
Naltrexone Showing More Potential in Drug Addiction Treatment Market Feb 05 2017 
John Paulson's Bargain Stock Jan 30 2017 
Teva: Good Value, Questionable Management? Jan 02 2017 
Integer Investments: Akorn Has 100% Upside Potential Jan 01 2017 
4 Stocks Reach Their 3-Year Low Prices Dec 31 2016 
10 for 2017! Investment Picks for the New Year Dec 23 2016 
Teva Is a Hold Nov 30 2016 
Buy Health Care Now? It All Depends on the Election Nov 07 2016 

More From Other Websites
Teva Is Expected to See a Fall in Its Profit Margins in 2017 Feb 23 2017
Teva Is Expected to Witness a Modest Revenue Rise in 2017 Feb 23 2017
What Analysts Recommend for Teva Pharmaceutical in 2017 Feb 23 2017
Billionaire Andreas Halvorsen’s Viking Global Cuts Losses and Dumps Southwestern Energy and Teva... Feb 23 2017
Manufacturing Delay Of Generic Drug From Pfizer Inc. (PFE) A Relief For Teva Pharmaceutical... Feb 22 2017
TEVA PHARMACEUTICAL INDUSTRIES LTD Financials Feb 22 2017
Momenta, Pfizer Give Teva Pharma Breathing Room On Generic MS Drug Feb 21 2017
Teva Shares Get a Boost in Early Trading Feb 21 2017
Billionaire Value Investor Michael Price Adds Specialty Retailer and a REIT to Its 13F Portfolio Feb 20 2017
This Keeps Driving Sanofi’s Growth Feb 20 2017
Parsabiv Is Expected to Boost Amgen’s Revenues in 2017 Feb 17 2017
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017
What's Driving Lilly's (LLY) Shares after 2016 Decline? Feb 16 2017
Multinationals learn the limits of being big Feb 16 2017
Teva seeks CEO with pharma background to lead recovery efforts Feb 13 2017
Drugmaker Teva says Israel probing kickback allegations Feb 08 2017
Drugmaker Teva says Israel probing kickback allegations Feb 07 2017
Teva CEO exits in ongoing crisis of confidence at drugmaker Feb 07 2017
Teva CEO exits in ongoing crisis of confidence at drugmaker Feb 07 2017
Teva says Israel probing same issues as U.S. bribery case Feb 07 2017
Teva names interim CEO, new chairman as Vigodman steps down Feb 06 2017
Teva names interim CEO, new chairman as Vigodman steps down Feb 06 2017
Asian shares mostly higher on strong manufacturing data Jan 31 2017
As Teva wins U.S. approval for GSK Advair copy, main fight yet to come Jan 30 2017
As Teva wins US approval for GSK Advair copy, main fight yet to come Jan 30 2017
Teva Announces Completion of Sale of UK and Ireland Actavis Assets and Operations Following European... Jan 09 2017
Israeli drugmaker Teva fined $519 mn in US for foreign bribes Dec 22 2016
Israeli drugmaker Teva fined $519 mn in US for foreign bribes Dec 22 2016
ANTARES PHARMA ANNOUNCES THE SUCCESSFUL COMPLETION OF TEVA’S DECENTRALIZED PROCEDURE FOR... Dec 19 2016
Actavis UK raised drug prices 12,000 pct, watchdog finds Dec 16 2016
Exclusive - Teva investigating allegations by tipster of bribery in Romania Dec 07 2016
Teva Receives Positive Outcome for COPAXONE® Label in Europe Dec 06 2016
Teva names Bhattacharjee as generics group head, replacing Olafsson Dec 05 2016
Teva names Bhattacharjee as generics group head, replacing Olafsson Dec 05 2016
Teva drugs help boost Mayne revenue Nov 28 2016
Teva drugs help Mayne to strong start Nov 28 2016
Teva trims 2016 outlook on drug launch delays Nov 15 2016
Israeli billionaire Nacht bets big money on another Teva in healthcare Nov 15 2016
ISS Mexico wins contract with Teva Pharmaceuticals Nov 10 2016
Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs Oct 17 2016
Teva Receives Positive Opinion from European Medicines Agency’s Committee for Medicinal Products... Oct 17 2016
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership Oct 06 2016
Deals of the day- Mergers and acquisitions Oct 05 2016
Teva to sell Allergan's generics business in UK, Ireland for $769 million Oct 05 2016
Teva to sell Allergan's generics business in UK, Ireland for $769 million Oct 05 2016
Teva to sell Allergan's generics business in UK, Ireland for $769 million Oct 05 2016
Teva Announces Sale of UK and Ireland Actavis Assets and Operations Oct 05 2016
Regeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an... Sep 20 2016
Teva, Intel to develop wearable tech for Huntington's disease Sep 15 2016
Teva, Intel to develop wearable technology for Huntington's disease Sep 15 2016
Teva and UGG Unveil Hybrid Collection Sep 15 2016
Teva to Present Latest Data in Multiple Sclerosis at 2016 ECTRIMS Congress in London Sep 07 2016
MDxHealth and Teva Pharmaceuticals Sign Distribution Agreement for SelectMDx in Israel Aug 31 2016
Teva to Present New Respiratory Data at the 2016 European Respiratory Society (ERS) International... Aug 30 2016
Teva Pharm eyes more acquisitions after buying Allergan's generics business Aug 04 2016
Dr. Reddy’s Completes Acquisition of Product Portfolio from TEVA Aug 03 2016
Allergan to sell Anda drug distribution business to Teva Aug 03 2016
Teva completes $40 bn purchase of Allergan generics arm Aug 02 2016
Teva completes $40 bn purchase of Allergan generics arm Aug 02 2016
Teva, Allergan win U.S. antitrust approval for generics deal Jul 27 2016
Teva, Allergan win U.S. antitrust approval for generics deal Jul 27 2016
Teva, Allergan win U.S. antitrust approval for generics deal Jul 27 2016
Five high-grade issuers announce deals Jul 20 2016
TEVA and Antares Pharma Announce Launch of Generic Imitrex in the United States Jun 27 2016
Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd. Jun 16 2016
Mesoblast shares tank after Teva exit Jun 14 2016
Mesoblast shares drop on outlook concerns Jun 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)